ライフサイエンスコーパス: thromboxane receptor

1 h is mediated, in part, by activation of the thromboxane receptor.

2 +) ionophore or by agonists for thrombin and thromboxane receptors.

3 s as a signaling protein in association with thromboxane receptors.

4 ation of Sp1 contributes to up-regulation of thromboxane receptors.

5 gonists, they are unlikely to be mediated by thromboxane receptors.

6 selectively blocked both ADP-stimulated and thromboxane receptor agonist U46619-stimulated platelet

7 ings preconstricted by 10(-6) M of U46619, a thromboxane receptor agonist, either in the presence or

8 ouse platelets by thrombin but not U46619, a thromboxane receptor agonist.

9 at seven positions throughout the human K562 thromboxane receptor and analyzed mutant receptor radiol

10 d two contribute to proper ligand binding to thromboxane receptors and show the importance of discret

11 c acid (14) with Kd = 9.9 +/- 0.4 nM for the thromboxane receptor antagonism and IC50 = 55.0 +/- 17.9

12 amine, antioxidant treatment with Tempol and thromboxane receptor antagonism with SQ-29548) were show

13 The thromboxane inhibitors tested were a thromboxane receptor antagonist (TXRA) and a thromboxane

14 leukotriene synthesis inhibitor, n = 5; and thromboxane receptor antagonist, n = 6).

15 oxygenase inhibitor, or SQ29548, a selective thromboxane receptor antagonist.

16 ese effects are prevented by pharmacological thromboxane receptor antagonists, they are unlikely to b

17 tease-activated receptor-1) antagonists, and thromboxane receptor antagonists.

18 tion was abolished by combined histamine and thromboxane receptor antagonists.

19 (positions 68 and 257) had little effect on thromboxane receptor binding or signaling.

20 (position 183) extracellular loop eliminated thromboxane receptor binding, consistent with the existe

21 Thromboxane receptor blockade lowered TNF and leukotrien

22 with little further antagonism by additional thromboxane receptor blockade.

23 nce rates also occurred in the presence of a thromboxane receptor blocker (n = 4), even when blood le

24 Chronic nitric oxide synthase I and thromboxane receptor deficiency did not change TGF respo

25 racellular loop, especially cysteine 223, in thromboxane receptor-effector coupling.

26 ggest that modulation of Sp1 levels controls thromboxane receptor expression during megakaryocytic di

27 aracterized the promoter region of the human thromboxane receptor gene and localized PMA-responsive e

28 Heterologous thromboxane receptor gene promoter/thymidilate kinase re

29 tion, oxidation, or sulfhydryl alkylation on thromboxane receptors have suggested a role for cysteine

30 Expression of platelet thromboxane receptors is transcriptionally increased dur

31 pi PGF2alpha does not activate either of the thromboxane receptor isoforms described in platelets.

32 or and caused only minimal activation of the thromboxane receptor isoforms stably expressed in HEK 29

33 response directly, via either of the cloned thromboxane receptor isoforms stably expressed in human

34 pe were found in nitric oxide synthase I and thromboxane receptor knockout mice.

35 the rank order of affinities for a series of thromboxane receptor ligands to bind to cloned human TPa

36 ipase A2, cyclooxygenase, or blockade of the thromboxane receptor markedly reduced the effects of H2S

37 ncreased Sp1 mRNA levels prior to increasing thromboxane receptor mRNA, suggesting that up-regulation

38 n potential.(1) Their studies reveal a novel thromboxane receptor mutation (TP-V241G) in humans that

39 EP2/DP on preosteoclasts and subtype EP1 and thromboxane receptors on stromal/osteoblast cells.

40 Inhibition of the thromboxane receptor or cyclooxygenase-2 dramatically at

41 sed placental or endothelial isoforms of the thromboxane receptor or for binding of thromboxane ligan

42 cement by activating PGF(2alpha) receptor or thromboxane receptor, or approximately 15% enhancement b

43 nocytes and macrophages depends on autocrine thromboxane receptor signaling and that under normal con

44 d LDL-mediated PGIS nitration and associated thromboxane receptor stimulation might be important in t

45 effect of 8-iso-PGF2alpha was mimicked by a thromboxane receptor (TP) agonist (U46619) and blocked b

46 However, although a single thromboxane receptor (TP) gene has been identified, two

47 is a GTP binding protein that couples to the thromboxane receptor (TP), but also functions as tissue

48 TXA2 and isoprostanes) which act through the thromboxane receptor (TP).

49 aglandin E(2) receptor subtype 4 (EP(4)) and thromboxane receptor (TP).

50 L receptor-deficient mice) by activating the thromboxane receptor (TP).

51 ndertaken to determine the potential role of thromboxane receptors (TP) in bladder cancer.

52 menon by demonstrating that H1 histamine and thromboxane receptors utilize the same mechanism to augm

53 ependent on a non-thromboxane agonist of the thromboxane receptor, whereas vasodilatory mechanisms of